Frovocimab

Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9[1].

Product Specifications

CAS Number

[1643672-70-1]

Product Name Alternative

LY 3015014

UNSPSC

12352203

Target

PCSK9

Type

Inhibitory Antibodies

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/frovocimab.html

Purity

99.87

Solubility

10 mM in DMSO

Smiles

[Frovocimab]

Molecular Weight

(146.38 kDa)

References & Citations

[1]Krista M Schroeder, et al. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. J Lipid Res. 2015 Nov;56 (11) :2124-32.